A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
| Autor: | Steven D. Nathan, Adrian Shifren, Adam L Anderson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Pyridones Administration Oral Medication Adherence law.invention 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine Patient Education as Topic Randomized controlled trial law medicine Humans Pharmacology (medical) 030212 general & internal medicine Intensive care medicine Adverse effect Randomized Controlled Trials as Topic business.industry Anti-Inflammatory Agents Non-Steroidal General Medicine Pirfenidone medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases Discontinuation Clinical trial 030228 respiratory system Tolerability Physical therapy Observational study business medicine.drug |
| Zdroj: | Expert Opinion on Drug Safety. 15:975-982 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1080/14740338.2016.1187129 |
| Popis: | Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most commonly encountered in an older population, therapeutic options should be not only effective, but also free from drug interactions and as safe and tolerable as possible.Comprehensive data from randomized controlled trials, meta-analyses, safety studies, and post-marketing data are available to assess the efficacy and safety of pirfenidone in the treatment of IPF. Information on efficacy, adverse events, drug tolerability and discontinuation rates both in clinical trials and real-world clinical experiences are reported.Pirfenidone has an abundance of data supporting its use in mild-to-moderate IPF. Observational evidence suggests a similar efficacy in severe IPF. In clinical trials, observational studies and real-world use, adverse events are frequent, though generally mild and well tolerated, especially with adequate patient education. Preventative strategies, along with timely and appropriate management of adverse events are critical in improving patient compliance, thereby ensuring the benefits of long-term treatment with pirfenidone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|